Excellergy has been snapped up by the Swiss pharma only five months after emerging with $70 million in funds. The Palo Alto, ...

The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than ...

Amid an outpouring of pharma investment dollars into China, Novartis is the latest multinational drugmaker lining up to ...

Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, ...

FRANKFURT, March 20 (Reuters) - Swiss drugmaker Novartis on Friday agreed to buy a breast cancer drug candidate for up to $3 ...

Novartis has reached an agreement to buy a PI3K-targeting drug for breast cancer from Synnovation Therapeutics, paying a ...

Novartis agrees to acquire Excellergy for up to $2 billion to boost immunology pipeline and expand US presence ...

Swiss pharmaceutical giant Novartis has announced plans to acquire California-based biotechnology company Excellergy in a ...

Swiss pharmaceutical giant Novartis said it plans to spend more than CNY3.3 billion (USD460 million) in China, using around ...

Novartis is teaming up with Microsoft on a new artificial intelligence initiative focused on drug discovery and development. The new efforts will primarily be focused in Novartis’ newly announced AI ...

Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer ; The lead ...

Novartis will acquire a breast cancer drug candidate from Synnovation Therapeutics in a deal worth up to $3 billion, boosting ...